期刊
CANCER BIOLOGY & THERAPY
卷 10, 期 7, 页码 658-664出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.10.7.13247
关键词
RCC; signaling pathways; kinases; mTOR; targeted therapy; genetics; epigenetics
类别
资金
- National Cancer Institute [P30 CA006927]
- Fox Chase Cancer Center
Renal cell carcinoma (RCC), the most lethal type of genitourinary cancer, is generally resistant to chemotherapy and radiation therapy. Surgical excision of the tumor at a localized stage remains the mainstay for curative therapy. A number of drugs developed in recent years have shown limited to significant efficacy in treating RCC. These drugs act by blocking critical signaling pathways associated with RCC tumor growth and survival and angiogenesis. Beyond well-validated signaling targets such as VHL, VEGFR and mTOR, additional pathways including HGF/c-MET and Wnt/beta-catenin have emerged as important to RCC pathogenesis. Mutations in one or more components of these signaling networks may affect tumor response to therapy. This review summarizes the state of knowledge about signaling pathways in RCC and discusses the known genetic and epigenetic alterations that underlie dysregulation of these pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据